

MLC Global Private Equity Fund – Class A

Investment update to 31 December 2024

Fund commentary

The MLC Global Private Equity Fund – Class A (the Fund) delivered a 10.3% net return over the December quarter.

Unlisted private equity co-investments and funds contributed 45% and 34% respectively to the gross Fund return for the quarter in AUD terms. Asian and US co-investments, as well as Asian and US fund investments, were the key contributors to performance during the quarter in AUD terms.

Sinopec, a co-investment made alongside the Chinese and South East Asian private equity investor RRJ Capital, was a strong performer (18% of the returns from co-investments). Sinopec is the largest distributor of petroleum products (including refined oil, natural gas and fuel oil) in China. Sinopec's domestic sales volume continues to increase in China following the recovery from COVID-19. Arcadia Consumer Healthcare ("Arcadia"), a co-investment alongside Bansk Group, is a US consumer health and wellness platform

comprising a branded portfolio of differentiated products. Arcadia contributed 8.2% of the returns from co-investments, as it continues to record strong revenue and EBITDA growth, with its largest brand Nizoral becoming the leading clinical dandruff shampoo. Arcadia is focused on securing additional production capacity for Nizoral, with the existing supplier currently executing on planned expansion which will significantly increase supply and enable additional marketing investment behind the brand.

The Fund is well diversified and holds 32 mid-market private equity co-investments and 46 private equity funds globally.

At the Fund level, the ETF and cash liquidity contributed 21% to gross returns for the quarter. The Australian dollar fell through the three months period to a near two-year low, benefiting the fund, with currency movements contributing positively to performance.

For the year ended 31 December 2024 the Fund has delivered a 19.9% return, and a 9.0% per annum return since inception.

Performance

	1 month (%)	3 months (%)	6 months (%)	1 year (%)	2 years (% pa)	Since inception (% pa)	
MLC Global Private Equity Fund –Class A	2.6%	10.3%	15.1%	19.9%	12.1%	9.0%	

Value of \$100,000 invested since inception



Performance by month

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov#	Dec	CYTD*
2022	-	-	-	-	-	-	-	-	-	-	-1.2%	-2.9%	-4.1%
2023	-2.1%	3.3%	1.3%	1.9%	1.3%	-0.6%	-0.5%	4.0%	-0.3%	0.2%	-2.0%	-1.5%	4.9%
2024	2.2%	4.2%	1.0%	-1.4%	-1.2%	-0.6%	3.6%	1.2%	-0.4%	4.1%	3.2%	2.6%	19.9%


Past performance is not a reliable indicator of future performance. The value of an investment may rise or fall with changes in the market. The returns shown on this page are calculated based on the net asset value of units issued in Class A of the Fund. The returns are net of management fees, performance fees, and indirect costs. The Fund's - Class A inception date is 31 October 2022.

*CYTD - calendar year to date.

Top holdings


Holding name	Investment type	Strategy	Region	Vintage*
PetSmart	Co-Investment	Buyout	North America	2015
Delta Capital Growth Fund II	Fund	Growth	Emerging markets	2017
Design Holding	Co-Investment	Buyout	Europe	2014
FLO	Co-Investment	Growth	Emerging markets	2014
Sinopec	Co-Investment	Growth	Emerging markets	2015

Asset allocation



Asset allocation shown as a percentage of NAV.¹ Region and sector data excludes listed private equity and cash.² Sector allocations are effective as at 30/09/2024. Numbers may not add to 100% due to rounding.

Investment year#



"Investment year allocation shown as a percentage of NAV, excluding listed private equity and cash. Effective date 30/09/2024. Numbers may not add to 100% due to rounding. Investment year indicates the year in which capital was invested into an asset.

*Vintage year indicates the year in which capital was committed to an investment of the Fund.

Market commentary

There are promising indicators of recovery in the market, as can be seen by the total number of global buyout¹ transactions starting to recover from the trough recorded in 2023, with transaction volumes rising 4% in 2024. Meanwhile, aggregate buyout deal value increased 13% from 2023 to 2024. MLC believe that there is attractive return potential in the fund:

- Median global buyout EV/EBITDA multiples are 32% below public markets as of 31 December 2024, with buyout valuations at 10.9x EBITDA compared to the S&P500 which finished the year with an EV/EBITDA multiple of 16.1x. PE valuations remain in line with 10 year averages.
- There has been a rebound in exit activity as PE exits rose throughout 2024, with many of our managers actively exploring sale processes for assets. Pressure to return LP capital persisted throughout 2024 in a tough

- fundraising environment, and managers are increasingly using strategies such as continuation vehicles ("CVs") to unlock liquidity, with 2024 CV exits up 12.9% year-on-year.
- With record levels of 'dry powder' (ie capital raised by PE funds but not yet invested) available to be deployed, and the bulk of the dry powder raised by large-cap PE funds, there is a large pool of capital available to acquire investments from our mid-market PE managers when these investments go to exit, with large cap PE often buying from mid-cap PE.
- In a challenging macro-economic and geopolitical environment, MLC remains focused on mid-market, recession resilient businesses with strong growth potential, backed by high quality PE managers who can create value through a variety of operational initiatives.

New investments in the quarter


Holding name	Manager	Investment type	Strategy	Region	Sector/ Market	Description
PETSMART	BC PARTNERS	Co- Investment	Buyout	North America	Consumer	Specialty retailer that is a market leading pet company in North America.
Project Alpha	UK mid- market manager	Co- Investment	Structured Equity	Europe	Energy	An investment into a portfolio of North Sea oil and gas assets, which has been sold and is awaiting distributions.
FOUNDATION WELLNESS	Bansk	Co- Investment	Buyout	North America	Consumer	Designs, manufactures and markets branded premium orthotics.
PRINCE STERLIZATION SERVICES	VANCE ST. CAPITAL	Co- Investment	Buyout	North America	Industrials	Leading provider of sterilisation products and services to pharmaceutical, biotechnology, compounding pharmacy and medical device sectors.
PETIQ Smarter Pet Health	Bansk	Co- Investment	Buyout North America Consumer		Consumer	Pet health & wellness company that manufactures and distributes a diverse portfolio of branded medications, dental chews and other wellness products for companion pets.
Bansk Fund II	Bansk	Fund - primary	Buyout	North America Mid-market		US middle market buyout manager exclusively focused on building leading consumer product businesses and platforms.
Frontier Fund I	Five V/Capital	Fund - primary	Buyout	Developed Asia	Lower mid- market	Focused on profitable Australasian lower mid-market companies in technology, business services, IT services and healthcare.
THE VOMELA COMPANIES	Riverside.	Co- Investment	Buyout	North America	Industrials	Provider of end-to-end marketing displays for retail, transportation, commercial and live event markets.

-

¹ Excluding add-ons

Distributions received by the Fund

Through the quarter, the Fund received 22 distributions totalling \$6.9m.



*Distributions include monies received by the Fund as a result of realisations of underlying companies, recapitalisations or dividends from coinvestments and private equity fund holdings. The Fund will attribute taxable income to investors even though it does not distribute its income to investors.

Case study



Overview

PetIQ is a recent co-investment made alongside MLC core PE manager Bansk, representing a take-private transaction, as PetIQ was previously NASDAQ listed. PetIQ develops, manufactures, markets and distributes a diverse portfolio of branded medications, dental chews and other wellness and nutritional products for companion pets, and operates veterinary services via Community Clinics and Wellness Centres.

Bansk monitored the business and the industry for more than 2 years prior to investment, which included consistent dialogue with management. MLC PE has maintained a 13-year relationship with the senior leadership at Bansk, a relationship that significantly predates Bansk Fund I (2021).

Value creation

Value creation is underway, with Bansk leveraging their expertise in the consumer packaged goods ("CPG") sector to reposition PetIQ as a pure-play CPG focused pet health provider. Bansk's playbook for PetIQ will involve driving mix shifts toward higher margin owned brands, exiting non-core business segments, reorganising the business model, pursuing strategic M&A and investing in new product innovation.



Key deal attractions

Differentiated platform: PetIQ is a high-quality, differentiated asset representing one of the only companies of scale in the pet wellness and healthcare segment.

Resilient, growing market: PetIQ will employ organic reinvestment and strategic M&A to drive market share gains in the growing pet wellness market.

Simplification and efficiency: The take-private nature of the transaction represented an opportunity to purchase a quality scaled asset at an attractive entry valuation. Pressure from public markets to grow at the top line limited the business' repositioning. Private ownership will allow Bansk to create a simplified, scaled and optimised business, repositioned as a pure-play CPG focused pet health provider.

Specialist manager: Bansk is a specialist consumer-focused PE manager with extensive experience managing OTC consumer health brands, and are well-positioned to execute against core value creation levers.





Further information

Visit our website at mlcam.com.au for the latest resources and insights from our investment experts.

Fund details

APIR code	MLC5609AU	Inception date	Class A – 31 October 2022
Investment objective	The Fund aims to provide capital growth, over the long term, by investing predominantly in a diverse range of global private equity investments.	Platform availability	Expand Extra, BT Panorama, CFS Edge, CFS FirstWrap, HUB24, Macquarie Wrap, Netwealth, North, Powerwrap, Praemium and Rhythm.
Hedging	Unhedged. Foreign currency exposures will generally not be hedged to the Australian dollar.	Investment horizon	7 to 10 years

Research house ratings







Important information

This communication is issued by MLC Investments Limited (ABN 30 002 641 661, AFSL 230705), part of the Insignia Financial Group of companies (comprising Insignia FinancialLtd ABN 49 100 103 722 and its related bodies corporate) ('Insignia Financial Group'). No other member of the Insignia Financial Group guarantees or otherwise accepts any liability in respect of any financial product referred to in this communication.

This communication may constitute general advice. It has been prepared without taking account of any investor's objectives, financial situation or needs.

Any investment returns and performance referred to in this communication are not guaranteed. An investment in the MLC Global Private Equity Fund is subject to investment risk, including possible delays in the repayment of capital and loss of income and principal invested.

Before making any investment decision, investors should obtain a Product Disclosure Statement (PDS) and Target Market Determination (TMD) for the MLC Global Private Equity Fund issued by MLC Investments Limited. A copy of the PDS and/or TMD is available upon request by phoning the MLC call centre on 132 652 or on our website at mlcam.com.au

Past performance is not a reliable indicator of future performance. The value of an investment may rise or fall with changes in the market. Actual returns may vary from any target return described in this communication and there is a risk that the investment may achieve lower than expected returns. Any projection or other forward-looking statement ('Projection') in this document is provided for information purposes only. No representation is made as to the accuracy of any such Projection or that it will be met. Actual events may vary materially.

This communication is directed to and prepared for Australian residents only. Any opinions expressed in this communication constitute our judgement at the time of issue and are subject to change. We believe that the information contained in this communication is correct and that any estimates, opinions, conclusions or recommendations are reasonably held or made as at the time of compilation. However, no warranty is made as to their accuracy or reliability (which may change without notice) or other information contained in this communication.

*If you are a financial adviser and would like a copy of the Zenith report, please contact us. The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned February 2024) referred to in this piece is limited to "General Advice" (\$766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines.

**If you are a financial adviser and would like a copy of the rating and report, please contact us. The rating referenced on this website is issued by SQM Research Pty Ltd ABN 93 122 592 036 AFSL 421913. SQM Research is an investment research firm that undertakes research on investment products exclusively for its wholesale clients, utilising a proprietary review and star rating system. The SQM Research star rating system is of a general nature and does not take into account the particular circumstances or needs of any specific person. The rating may be subject to change at any time. Only licensed financial advisers may use the SQM Research star rating system in determining whether an investment is appropriate to a person's particular circumstances or needs. You should read the product disclosure statement and consult a licensed financial adviser before making an investment decision in relation to this investment product. SQM Research receives a fee from the Fund Manager for the research and rating of the managed investment scheme.

***The rating issued October, 2023 MLC5609AU MLC Global Private Equity Fund, is published by Lonsec Research Pty Ltd ABN 11151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2023 Lonsec. All rights reserved.